Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

China Nixes Hospital Adjustment Fees As Measure To Reduce Drug Prices

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - In an effort to reduce drug prices, China will cancel drug adjustment fees in hospitals as part of its health care reform plan, the Ministry of Health announced during a press conference here Jan. 12

You may also be interested in...



Chinese Premier Wen Jiabao Allocates Healthcare Investment, But Essential Drug List Delayed Again

SHANGHAI - China's State Council issued additional healthcare reform plans July 8 to detail the goals of the country's ambitious reform plan. However, the release of the long-awaited essential drug list will be delayed to the end of this year, which was expected to be issued by June

Chinese Premier Wen Jiabao Allocates Healthcare Investment, But Essential Drug List Delayed Again

SHANGHAI - China's State Council issued additional healthcare reform plans July 8 to detail the goals of the country's ambitious reform plan. However, the release of the long-awaited essential drug list will be delayed to the end of this year, which was expected to be issued by June

China Establishes Essential Drug List Committee To Deal With Conflicts Of Interest

SHANGHAI - China's Ministry Of Health announced May 11 a national essential drug working committee to solve conflicts that arose while drafting the essential drug list

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

SC069817

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel